Anthropic Launches HIPAA-Compliant Healthcare Tools for Claude AI Amid Growing Competition 
Amazon Reviews Supplier Costs as U.S.–China Tariffs Ease 
Lynas CEO Amanda Lacaze to Retire After 12 Years as Rare Earths Demand Grows 
Coca-Cola Shelves Costa Coffee Sale After Low Private Equity Offers 
AFT Leaves X Over AI-Generated Images of Minors 
Trump Administration Approves Nvidia H200 AI Chip Sales to China Under New Export Rules 
BESI Reports Strong Q4-25 Orders Surge Driven by Data Center and Hybrid Bonding Demand 
Nvidia Denies Upfront Payment Requirement for H200 AI Chips Amid China Export Scrutiny 
Starlink Internet Remains Active in Iran Despite Nationwide Blackout 
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
SK Hynix to Invest $13 Billion in Advanced Chip Packaging Plant as AI Memory Demand Surges 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
Taiwan Issues Arrest Warrant for OnePlus CEO Over Alleged Illegal Recruitment Activities 
U.S. Government Invests $1 Billion in L3Harris Rocket Motor Business to Secure Missile Supply Chain 
BlueScope Steel Announces A$1 Special Dividend After Asset Sales 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
AbbVie Commits $100 Billion to U.S. Investment in Drug Pricing Deal With Trump Administration 
NEW YORK, March 31, 2017 -- Guggenheim Securities, the investment banking and capital markets division of Guggenheim Partners, announced today that Adnan Butt will join the firm as a Managing Director to expand Healthcare coverage on the Equities platform. Mr. Butt will join Guggenheim on the Healthcare research team in June, specifically focusing on biotechnology companies.
Mr. Butt joins Guggenheim from RBC Capital Markets, where he was a Biotechnology Analyst. Prior to RBC, he covered biotechnology at ThinkEquity Partners, Morgan Stanley, and J.P. Morgan & Co.
“We are excited for Adnan to join our team,” said Jerry Donini, Co-CEO of Guggenheim Securities. “His deep industry knowledge provides a significant expansion to our Healthcare platform, building on our existing research presence in specialty pharmaceuticals, major pharmaceuticals, biotechnology, and medical devices and supplies. We look forward to his success at Guggenheim.”
Mr. Butt received his M.A. in Economics from Trinity College and his M.A. in Neuroscience from the University of Hartford; he received his B.A. in Economic and Molecular Biology & Biochemistry from Wesleyan University. He will be based in Guggenheim’s San Francisco office.
About Guggenheim Partners
Guggenheim Partners is a global investment and advisory firm with more than $260 billion1 in assets under management. Across our three primary businesses of investment management, investment banking, and insurance services, we have a track record of delivering results through innovative solutions. With more than 2,300 professionals based in more than 25 offices around the world, our commitment is to advance the strategic interests of our clients and to deliver long-term results with excellence and integrity. We invite you to learn more about our expertise and values by visiting GuggenheimPartners.com and following us on Twitter at twitter.com/guggenheimptnrs.
1 Assets under management are as of 12.31.2016 and include consulting services for clients whose assets are valued at approximately $63bn.
Media Contact Ellen Cunningham Guggenheim Partners 212.518.9578 [email protected]
